Literature DB >> 17335463

Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey.

E Bruckert1, M Baccara-Dinet, E Eschwege.   

Abstract

AIMS: To measure the prevalence of low high-density lipoprotein (HDL)-cholesterol (men < 1.03 mmol/l; women < 1.29 mmol/l) in European Type 2 diabetic patients receiving treatment for dyslipidaemia.
METHODS: The pan-European Survey of HDL-cholesterol measured lipids and other cardiovascular risk factors in 3866 patients with Type 2 diabetes and 4436 non-diabetic patients undergoing treatment for dyslipidaemia in 11 European countries.
RESULTS: Diabetic patients were more likely to be obese or hypertensive than non-diabetic patients. Most patients received lifestyle interventions (87%) and/or a statin (89%); treatment patterns were similar between groups. Diabetic patients had [means (SD)] lower HDL-cholesterol [1.22 (0.37) vs. 1.35 mmol/l (0.44) vs. non-diabetic patients, P < 0.001] and higher triglycerides [2.32 (2.10) vs. 1.85 mmol/l (1.60), P < 0.001]. More diabetic vs. non-diabetic patients had low HDL-cholesterol (45% vs. 30%), high triglycerides (> or = 1.7 mmol/l; 57% vs. 42%) or both (32% vs. 19%). HDL-cholesterol < 0.9 mmol/l was observed in 18% of diabetic and 12% of non-diabetic subjects. Differences between diabetic and non-diabetic groups were slightly greater for women. LDL- and total cholesterol were lower in the diabetic group [3.02 (1.05) vs. 3.30 mmol/l (1.14) and 5.12 (1.32) vs. 5.38 mmol/l (1.34), respectively, P < 0.001 for each].
CONCLUSIONS: Low HDL-cholesterol is common in diabetes: one in two diabetic women has low HDL-cholesterol and one diabetic man in four has very low HDL-cholesterol. Management strategies should include correction of low HDL-cholesterol to optimize cardiovascular risk in diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17335463     DOI: 10.1111/j.1464-5491.2007.02111.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  12 in total

1.  Paradoxical negative HDL cholesterol response to atorvastatin and simvastatin treatment in Chinese type 2 diabetic patients.

Authors:  Yu-Hung Chang; Kun-Cheng Lin; Dao-Ming Chang; Chang-Hsun Hsieh; Yau-Jiunn Lee
Journal:  Rev Diabet Stud       Date:  2013-08-10

2.  Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS).

Authors:  S Horgan; J Crowley; J Feely; B McAdam; E Shanahan; C Vaughan
Journal:  Ir J Med Sci       Date:  2011-03-13       Impact factor: 1.568

3.  Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD.

Authors:  Michel P Hermans
Journal:  Curr Cardiol Rev       Date:  2010-05

Review 4.  Lipid goals in metabolic syndrome and diabetes.

Authors:  Helen M Colhoun
Journal:  Curr Atheroscler Rep       Date:  2007-10       Impact factor: 5.113

5.  Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol.

Authors:  Manabu Ogita; Katsumi Miyauchi; Tadashi Miyazaki; Ryo Naito; Hirokazu Konishi; Shuta Tsuboi; Tomotaka Dohi; Takatoshi Kasai; Takayuki Yokoyama; Shinya Okazaki; Takeshi Kurata; Hiroyuki Daida
Journal:  Heart Vessels       Date:  2013-03-21       Impact factor: 2.037

6.  Involvement of ATP-binding cassette, subfamily A polymorphism with susceptibility to coronary artery disease.

Authors:  Seema Zargar; Salma Wakil; Abduelah F Mobeirek; Abdulaziz A Al-Jafari
Journal:  Biomed Rep       Date:  2013-09-02

7.  Serum lipid profile and its association with hypertension in Bangladesh.

Authors:  Kamrun Nahar Choudhury; A K M Mainuddin; Mohammad Wahiduzzaman; Sheikh Mohammed Shariful Islam
Journal:  Vasc Health Risk Manag       Date:  2014-06-30

8.  Impact of low high-density lipoprotein-cholesterol level on 2-year clinical outcomes after acute myocardial infarction in patients with diabetes mellitus.

Authors:  Hyung Joon Joo; Sang-A Cho; Soon Jun Hong; Seung-Ho Hur; Jang-Ho Bae; Dong-Ju Choi; Young-Keun Ahn; Jong-Seon Park; Rak-Kyeong Choi; Donghoon Choi; Joon-Hong Kim; Kyoo-Rok Han; Hun-Sik Park; So-Yeon Choi; Jung-Han Yoon; Hyeon-Cheol Kwon; Seung-Woon Rha; Kyung-Kuk Hwang; Kyung-Tae Jung; Seok-Kyu Oh; Jae-Hwan Lee; Eun-Seok Shin; Kee-Sik Kim; Hyo-Soo Kim; Do-Sun Lim
Journal:  Lipids Health Dis       Date:  2016-11-18       Impact factor: 3.876

Review 9.  Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.

Authors:  Anja Vogt; Ursula Kassner; Ulrike Hostalek; Elisabeth Steinhagen-Thiessen
Journal:  Vasc Health Risk Manag       Date:  2007

10.  Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS).

Authors:  D Devroey; R P Radermecker; B J Van der Schueren; B Torbeyns; R J Jaken
Journal:  Int J Clin Pract       Date:  2013-12-06       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.